MFC Co

MFC Co AAQS

The The AAQS of MFC Co (432980.KQ) as of Nov 5, 2026 is 1. In the previous year, The AAQS was 1.00 — a change of 0.00% (lower).

AAQS

1

YoY

0.00%

Last updated:

MFC Co has a current AAQS of 1.

A high AAQS can be seen as a positive indicator that the company is developing successfully.

Investors can assume that the company is on a good path to generate profits.

On the other hand, it is important to consider the AAQS of the stock MFC Co in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.

In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.

The MFC Co AAQS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

AAQS
Date
AAQS
Jan 1, 2022
1.00 KRW
Jan 1, 2023
1.00 KRW
Jan 1, 2024
1.00 KRW
The MFC Co AAQS history
YEARAAQSYoY
10.00%
10.00%
1—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

MFC Co Stock analysis

What does MFC Co do? MFC Co Ltd generates revenue primarily through the development and production of active pharmaceutical ingredients (API), key starting materials (KSM), and intermediate materials for the pharmaceutical industry. The company focuses on creating basic pharmaceutical substances and raw material pharmaceuticals, serving clients in the pharmaceutical sector. Its products are sold to pharmaceutical manufacturers who require these materials for drug formulation. The company operates within the pharmaceutical research and development segment, targeting firms involved in drug production and formulation. MFC Co Ltd's business model centers on providing essential raw materials and intermediates to pharmaceutical companies. By specializing in API, KSM, and intermediate materials, the company supports the manufacturing processes of its clients. The firm's revenue streams are derived from the sale of these specialized pharmaceutical components to manufacturers who integrate them into their final drug products. The company's target market consists of pharmaceutical manufacturers requiring high-quality raw materials for their production lines. The company's core offerings include active pharmaceutical ingredients (API), key starting materials (KSM), and intermediate materials, which are critical for pharmaceutical manufacturing. These products are sold to pharmaceutical manufacturers as part of their supply chain. MFC Co Ltd's revenue is generated through the direct sale of these materials to clients in the pharmaceutical industry. The company's focus on R&D for pharmaceutical substances ensures a steady demand for its products from drug manufacturers seeking reliable suppliers. MFC Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about MFC Co stock

The AAQS of MFC Co is 1 in 2024.

On Eulerpool you can find the complete historical development of The AAQS MFC Co since 2006 – with annual values, charts, and detailed analysis.

The AAQS is a key figure developed by AlleAktien.

The AAQS is a key figure developed by AlleAktien.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — MFC Co

All Key Metrics — MFC Co